Avonex 15 Year Long Term Follow-up Study

Completed

Conditions studied: Multiple Sclerosis

In brief

The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM IFNβ-1a treatment on long-term disability and Quality of Life outcomes in patients who completed 2 years in a previous Multiple Sclerosis Collaborative Research Group (MSCRG) study.

Key facts

Study ID

NCT00525343

Run by

Biogen

People needed

122

Starts

2007-03-01

Expected to finish

2008-09-01

Last updated by the study team

2010-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients having completed at least 2 years of treatment (Avonex® or placebo) in the original Avonex® pivotal trial.
• Subjects (or their caregivers) must be willing to complete a multi-page questionnaire.
• Signed written informed consent form

You may not qualify if…

• Unwillingness or inability to comply with the requirements of this protocol.
• Any other reasons that, in the opinion of the Investigator, the subject is determined to be unsuitable for enrollment into this study

Where it is running

• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Jocab's Neurological Institute — Buffalo, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Oregon Health and Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.